<DOC>
	<DOCNO>NCT02394665</DOCNO>
	<brief_summary>In summary , overall prognosis glioblastoma ( GBM ) patient remain poor . Although clinical gain achieve past , modest , majority patient succumb local disease progression within 2 year . New strategy treatment need identify enhance local control current treatment regimen order achieve clinical gain disease . Favorable early experience magnetic resonance spectroscopy imaging ( MRSI ) demonstrate metabolic image identify active tumor beyond standard MRI well high risk region risk local failure . There also clinical evidence limit field dose escalation either simultaneous integrate boost ( SIB ) stereotactic radiosurgery ( SRS ) feasible safe . Coupling finding provide rationale propose Phase II trial design define efficacy toxicity novel treatment approach whole brain volumetric 3D MRSI guide dose-escalated radiation therapy ( RT ) newly diagnose GBM patient .</brief_summary>
	<brief_title>Dose Escalated MRSI Guided Radiation Therapy Glioblastoma</brief_title>
	<detailed_description>This phase II study investigate efficacy safety volumetric 3D MRSI-directed treatment newly diagnose GBM patient . This study enroll 48 patient order obtain least 40 patient receive RT temozolomide . Depending size number HTVs , patient receive either simultaneous integrate boost ( SIB ) IMRT ( Group 1 ) SRS boost follow IMRT 1 week later ( Group 2 ) . Duration enrollment 2 year minimum follow-up 2 year . The duration treatment follow-up occur follow : - Six week RT concurrent Temozolomide treatment ; - 3D MRSI week 3 end RT ; - 28 day break ; - Adjuvant treatment Temozolomide administer daily day 1-5 cycle , 12 cycle ( one cycle = 28 day ) include standard gadolinium enhance MRI 3D MRSI prior cycle 1 , 5 , 9 , post cycle 12 adjuvant Temozolomide ; - Active follow-up least every three month one year end adjuvant Temozolomide treatment ; - After one year follow-up survival occur every three month one year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Histologically proven diagnosis glioblastoma ( WHO grade IV ) . Since gliosarcoma variant glioblastoma , gliosarcoma also eligible diagnosis . 2 . The tumor must supratentorial component 3 . Patients must recover effect surgery , postoperative infection complication 4 . Karnofsky performance status &gt; 70 5 . Age &gt; 18 year 6 . Adequate bone marrow function define follow : Absolute neutrophil count ( ANC ) &gt; /= 1500 cells/mm^3 Platelet count &gt; 100,000 cells/mm^3 Hemoglobin &gt; 10.0 g/dL ( Note : use transfusion intervention achieve Hgb &gt; 10.0 g/dL acceptable . ) 7 . Patients fulldose anticoagulant ( e.g. , warfarin lowmolecular weight ( LMW ) heparin ) must meet following criterion : No active bleeding pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) Inrange international normalize ratio ( INR ) ( usually 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin 8 . Adequate renal function , define follow : Blood urea nitrogen ( BUN ) &lt; 30 mg/dL Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) 9 . Adequate hepatic function , define : Bilirubin &lt; 1.5 normal range Alanine transaminase ( ALT ) &lt; 3x normal range Aspartate transaminase ( AST ) &lt; 3x normal range 10 . Patients must pregnant ( positive pregnancy test ) breast feeding ; pregnancy test must do within 7 day prior registration . Effective contraception ( men woman ) must use patient childbearing potential study treatment 6 month . 11 . Ability understand willingness sign write informed consent document 12 . Ability MRI Scans 13 . Ability swallow capsule 1 . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 3 year ( example , carcinoma situ breast , oral cavity cervix permissible ) 2 . Recurrent malignant glioma evidence leptomeningeal spread 3 . Metastases detect tentorium beyond cranial vault 4 . Prior use Gliadel wafer intratumoral intracavitary treatment 5 . Prior radiotherapy head neck ( except T1 glottic cancer ) , result overlap radiation therapy field 6 . Prior radiation therapy chemotherapy glioblastoma 7 . Severe , active comorbidity , define follow : Symptomatic congestive heart failure New York heart Association Class III IV Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within last 6 month , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease Severely impaired lung function define spirometry diffuse capacity lung carbon monoxide ( DLCO ) 50 % normal predict value and/or 02 saturation 88 % less rest room air Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN Active ( acute chronic ) uncontrolled severe infection require intravenous antibiotic Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis Acquired immune deficiency syndrome ( AIDS ) base upon current Centers Disease Control Prevention ( CDC ) definition know HIV seropositivity . Note , however , HIV test require entry protocol . The need exclude patient HIV/AIDS protocol necessary treatment involve protocol may significantly immunosuppressive . Active connective tissue disorder , lupus scleroderma , opinion treat physician may put patient high risk radiation toxicity Other major medical illness psychiatric impairment investigator 's opinion prevent administration completion protocol therapy 8 . Pregnancy 9 . Women breast feed 10 . Prior allergic reaction temozolomide 11 . Treatment therapeutic clinical protocol 12 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption temozolomide ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) 13 . Contraindications MRI include limited , pacemaker , aneurysm clip , neurostimulators , cochlear implant , metal eye , steelworker implant 14 . Need continue treatment prohibit medication ( e.g . antioxidant ) complete appropriate washout period .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>GBM</keyword>
</DOC>